当前位置：首页 > 文献互助 > 互助详情

A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis复制

用户TBS_MGy5GuJQ 9小时前 13 10 待确认 帖子自动结束时间: 2025-06-21 00:01:13

1. 请及时下载文件确认是否正确, 系统将在 2025-06-23 09:34:14 删除文件

2. 如若文件有误请驳回应助文件, 求助状态即回到求助中

3. 如若文件正确请及时点击确认, 若超过时后系统自动默认为已完结

注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规

DOI: 10.1016/j.kint.2024.02.024复制

文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0085253824001960复制

其他信息:

出版社: Elsevier BV
作者: Wolfgang C. Winkelmayer; Anthonie W.A. Lensing; Ravi I. Thadhani; Kenneth W. Mahaffey; Michael Walsh; Ákos F. Pap; Stefan Willmann; Kirstin Thelen; Sophie Hodge; Alexander Solms; Sheila J.M. Ingham; John Eikelboom

上一篇：An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

下一篇：In vivo inhibition of Helicobacter pylori through probiotics and gastrointestinal commensals: a critical review

互助时间线

2025-06-16 09:34:14 [上传文件]

用户lOjxaoibspYF上传了文件(pdf 893.25 KB), 求助状态变成 待确认

2025-06-16 00:01:13 [发起求助]

最新发布的求助

Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial 17分钟前
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial 18分钟前
超分子技术在化妆品中的应用与展望. 20分钟前
A new index of abdominal adiposity as an indicator of risk for cardiovascular disease. A cross-population study 1小时前
In vivo inhibition of Helicobacter pylori through probiotics and gastrointestinal commensals: a critical review 1小时前
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis 9小时前
An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors 14小时前
CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity 14小时前
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study 17小时前
Decade trends in risk factors, treatments, and prognosis of minor ischemic stroke and tia in china 17小时前
Encapsulation of Adipose-Derived Stem Cells in Collagen-Based Hydrogel 18小时前
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study 18小时前

wispass工作室 Copyright © 蜀ICP备2024051606号-2 www.wispass.com